Research programme: inner ear disorders therapies - DURECT/NeuroSystec

Drug Profile

Research programme: inner ear disorders therapies - DURECT/NeuroSystec

Latest Information Update: 26 Mar 2012

Price : $50

At a glance

  • Originator DURECT Corporation
  • Developer DURECT Corporation; NeuroSystec Corporation
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Tinnitus

Most Recent Events

  • 02 Mar 2012 Discontinued - Preclinical for Tinnitus in USA (unspecified route)
  • 10 Jul 2007 Preclinical development is ongoing
  • 12 Jul 2004 Preclinical trials in Tinnitus in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top